Hersteller |
GENWAY
|
Kategorie |
|
Typ |
Antibody |
Specific against |
other |
Clon |
Bu78 |
Applikationen |
FC |
Menge |
0.025 mg |
ArtNr |
20-783-310546 |
eClass 6.1 |
32160702 |
eClass 9.0 |
32160702 |
Lieferbar |
|
Genway ID: |
GWB-21C52F |
Specificity: |
CD45RA |
Specificity: |
CD45RA |
Clone: |
Bu78 |
Preparation: |
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant |
Buffer Solution: |
Phosphate buffered saline pH7. 4 |
|
Preservative Stabilisers: |
| 0. 09%Sodium Azide (NaN3) Suggested |
Flow Cytometry: |
Use 10ul of the suggested working dilution to label 1x106 cells in 100ul. Suggested |
Dilution: |
Flow Cytometry - 1/25 - 1/100 |
Function: |
Required for T-cell activation through the antigen receptor. The first PTPase domain has enzymatic activity while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation recruits an dephosphorylates SKAP1 and FYN. |
Catalytic Activity: |
Protein tyrosine phosphate + H2O = protein tyrosine + phosphate. |
Subunit: |
Binds GANAB and PRKCSH (By similarity). Interacts with SKAP1. |
Subcellular Location: |
Membrane; Single-pass type I membrane protein. |
Domain: |
The first PTPase domain interacts with SKAP1. |
Ptm: |
Heavily N- and O-glycosylated. |
Disease: |
Defects in PTPRC are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+)SCID) [MIM:608971]. SCID refers to a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity leukopenia and low or absent antibody levels. Patients with SCID present in infancy with recurrent persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development. |
Disease: |
Genetic variations in PTPRC are involved in multiple sclerosis susceptibility (MS) [MIM:126200]. MS is a neurodegenerative disorder characterized by the gradual accumulation of focal plaques of demyelination particularly in the periventricular areas of the brain. Peripheral nerves are not affected. Onset usually in third or fourth decade with intermittent progression over an extended period. The cause is still uncertain. |
Similarity: |
Belongs to the protein-tyrosine phosphatase family. Receptor class 1/6 subfamily. |
Similarity: |
Contains 2 fibronectin type-III domains. |
Similarity: |
Contains 2 tyrosine-protein phosphatase domains. |
Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.
Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.